Filtered By:
Condition: Headache
Nutrition: Herbs

This page shows you your search results in order of date.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Gastrodia elata Blume: A review of its mechanisms and functions on cardiovascular systems
Fitoterapia. 2023 Apr 17:105511. doi: 10.1016/j.fitote.2023.105511. Online ahead of print.ABSTRACTGastrodia elata Blume (GEB), commonly called Tianma in Chinese, is a valuable and extensively used herbal Traditional Chinese Medicine with a wide range of clinical applications. It has been used to treat headaches, dizziness, stroke, epilepsy, amnesia, spasm, and other disorders since ancient times. Hundreds of compounds, including Phenols, glycosides, polysaccharides, steroids, organic acids, and others, have been isolated and identified from this plant. Modern pharmacological studies have shown that its active ingredients p...
Source: Fitoterapia - April 17, 2023 Category: Biochemistry Authors: Xiaoning Sun Bo Jia Jingran Sun Jianguo Lin Bingjiu Lu Jinlong Duan Cheng Li Qingqing Wang Xin Zhang Meng Tan Dongsheng Zhong Xiaoxiao Zhang Ziyi Sun Yan Zhang Kuiwu Yao Source Type: research

New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Alternative medicine therapies in neurological disorders: Prevalence, reasons and associated factors. A systematic review
CONCLUSIONS: The prevalence of CAM use in neurological diseases is highly variable (16%-100%); the most used type of CAM was biological therapies and the associated factors were female sex, age between 40 and 50 years old and high socioeconomic level.PMID:36805318 | DOI:10.1016/j.ctim.2023.102932
Source: Complementary Therapies in Medicine - February 22, 2023 Category: Complementary Medicine Authors: Mar ía Soto-Lara Melissa Silva-Loredo Jos é Rodrigo Monroy-Córdoba Paola Flores-Ordo ñez Nelly G Cervera-Delgadillo Paul Carrillo-Mora Source Type: research

Recent applications of Kampo treatment for neurological diseases
ConclusionKampo medicine is being applied in new and effective ways to treat various neurological diseases. Hopefully, more clinicians will recognize the usefulness of such Kampo medicines and utilize them in their daily practice.
Source: Traditional and Kampo Medicine - January 5, 2023 Category: Complementary Medicine Authors: Shin ‐ichi Muramatsu, Mayumi Tamada, Yoshinao Harada, Masaki Raimura, Seungwon Kwon Tags: REVIEW Source Type: research

From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders
Aging is described as an advanced time-related collection of changes that may negatively affect with the risk of several diseases or death. Aging is a main factor of several age-related neurological disorders, including neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, and dementia), stroke, neuroinflammation, neurotoxicity, brain tumors, oxidative stress, and reactive oxygen species (ROS). Currently available medications for age-related neurological disorders may lead to several side effects, such as headache, diarrhea, nausea, gastrointestinal (GI) diseases, dyskinesia, and hallucinosis. These day...
Source: Frontiers in Pharmacology - November 10, 2022 Category: Drugs & Pharmacology Source Type: research

Potential therapeutics against neurological disorders: Natural products-based drugs
Neurodegenerative disorders, which are defined by the breakdown of neurons over time, are affecting an increasing number of people. Stroke, Alzheimer's, Parkinson's, Multiple Sclerosis, Migraine, and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have no cure. Besides, there is a huge demand for drugs that can cure the diseases mentioned above because the majority of the medications we use to treat them only alleviate diseases. Different neurological disorders have responded satisfactorily to the pharmacological effects of medicinal plants. Despite the numerous multiple types of plants in the...
Source: Frontiers in Pharmacology - August 19, 2022 Category: Drugs & Pharmacology Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Registration of intervention trials of Traditional Chinese Medicine for four neurological diseases on Chinese Clinical Trial Registry and ClinicalTrials.gov: a narrative review
CONCLUSIONS: Irregular and inadequate reporting, untimely update and publication, insufficient information on traditional medicine unique characteristics, and lack of international collaborations are the problems existing in the interventional clinical registration trials of traditional medicine treatment on neurological diseases. More efforts need to be made from the above aspects to standardize and improve the registration of traditional medicine trials.PMID:35322645 | DOI:10.19852/j.cnki.jtcm.2022.01.010
Source: Journal of Traditional Chinese Medicine - March 24, 2022 Category: Complementary Medicine Authors: Jing-Jing Wei Rong-Juan Guo Guo-Jing Fu Xiao Liang Zhen-Min Xu Xing Liao Min Jia Zi-Xiu Zeng Wan-Qing DU Wei-Wei Jiao Lin-Juan Sun Hong-Mei Liu Chun-Li Guo Chen-Guang Tong Yun-Ling Zhang Source Type: research